Kyverna Therapeutics, Inc.
KYTX · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 7.03M | 7.03M | -29.38M | -28.89M | -1.12 |
| 2023 FY | — | -1.71M | -62.41M | -60.37M | 0.00 |
| 2024 FY | — | -2.13M | -142.60M | -127.48M | -3.33 |
| 2025 FY | — | — | -169.83M | -161.31M | -3.64 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 66.92M | 20.25M | 37.74M | 10.56M | 46.68M |
| 2023 FY | 75.20M | 26.02M | 34.65M | 9.08M | 49.18M |
| 2024 FY | 304.65M | 38.06M | 96.62M | 8.24M | 266.59M |
| 2025 FY | 293.83M | 61.55M | 124.09M | 29.03M | 232.28M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -36.11M | -768.00K | -36.88M | — | -38.33M |
| 2023 FY | -52.41M | -621.00K | -53.03M | — | -3.08M |
| 2024 FY | -114.25M | -2.21M | -116.46M | — | 61.96M |
| 2025 FY | -153.71M | -5.00K | -153.72M | — | 27.47M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 774.12M | 746.95M | — | — | — |
| 2023 FY | 20.21B | 20.18B | — | — | — |
| 2024 FY | 143.37M | 54.99M | — | — | — |
| 2025 FY | 416.04M | 320.98M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | -515.00K | -44.41M | -42.08M | -0.97 |
| 2025 Q3 | — | — | -38.73M | -36.79M | -0.85 |
| 2025 Q4 | — | — | -39.28M | -37.80M | -0.80 |
| 2026 Q1 | — | -351.00K | -41.37M | -39.73M | -0.66 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 226.51M | 42.13M | 53.44M | 5.92M | 184.38M |
| 2025 Q3 | 187.16M | 35.21M | 34.16M | 5.02M | 151.95M |
| 2025 Q4 | 293.83M | 61.55M | 124.09M | 29.03M | 232.28M |
| 2026 Q1 | 257.02M | 61.44M | 32.19M | 33.76M | 195.58M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -31.95M | -204.00K | -32.15M | — | -3.43M |
| 2025 Q3 | -43.32M | -392.00K | -43.71M | — | -19.28M |
| 2025 Q4 | -33.53M | 5.00K | -33.52M | — | 89.93M |
| 2026 Q1 | -41.60M | — | -41.60M | — | -91.90M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 132.70M | 85.18M | — | — | — |
| 2025 Q3 | 260.49M | 231.35M | — | — | — |
| 2025 Q4 | 443.26M | 348.20M | — | — | — |
| 2026 Q1 | 521.55M | 523.11M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |